Related Experiment Video
Updated: Aug 27, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Trends in Buprenorphine Prescribing Among Adults with Opioid Use Disorder and Coexisting HIV or Viral Hepatitis,
Margaret G Miller1, Ashley Hailer1, Philip R Wang2
1Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Abstract:
We examined buprenorphine prescribing among adults in the United States with opioid use disorder or other opioid-related diagnoses and coexisting HIV, hepatitis B, or hepatitis C from 2015 to 2025. Using the TriNetX USA Minimal Date Shift Network, we constructed annual cohorts and assessed encounter-day buprenorphine prescribing, with and without chronic pain diagnoses. Prescribing rose from 6% in 2015 to 17% in 2020, then plateaued at 16-19% through 2025, with marked attenuation after 2020. Despite expanded prescriber eligibility, most were not prescribed buprenorphine at clinical contact, suggesting regulatory reform alone is insufficient and that integrated, systemic approaches are needed.
Related Concept Videos
Viral Hepatitis I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Retrovirus Life Cycles
Hepatitis
Therapeutic Drug Monitoring: Affecting Factors
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...